Terpene-loaded Liposomes and Isopropyl Myristate As Chemical Permeation Enhancers Toward Liposomal Gene Delivery in Lung Cancer Cells; A Comparative Study

Overview

Journal Iran J Pharm Res

Publisher Brieflands

Specialty Pharmacology

Date 2016 Dec 17

PMID 27980561

Citations 6

Authors

Mostafa Saffari

Farshad Hoseini Shirazi

Hamid Reza Moghimi

Affiliations

Soon will be listed here.

Abstract

Gene therapy is in its development stage as a novel method for cancer treatment. Liposomes look promising as gene delivery vectors; however, investigations have shown that these vesicles are not doing well in some cases. It was decided here to investigate the possibility of augmentation of liposomal gene delivery by chemical penetration enhancers. Cationic liposome containing antisense oligonucleotide (AsODN) against lung cancer was prepared by ethanol injection method. Liposomal cineole and limonene (as enhancers) were prepared by film hydration method. Isopropyl myristate (IPM) was also investigated as penetration enhancer. Liposomes were evaluated for their size, zeta potential and encapsulation efficiency. Cancer cells (A549) were pretreated with liposomal terpenes prior to treatment with liposomal antisense or scrambled oligonucleotide. Cell viability was evaluated by MTT assay. Oligonucleotide -containing liposome showed particle size of about115 nm and zeta potential of 0.6 mV. Liposomal cineole significantly (P<0.05) increased specific activity of liposomal antisense but limonene didn't show such an effect. IPM increased both specific and non-specific cytotoxicity of Oligonucleotide. These results show that penetration enhancers (such as cineole) may be used for improving liposomal gene delivery and to reduce non-specific toxicity. Concentration and chemical nature of enhancer has prominent effect in their efficacy.

Citing Articles

A Mechanistic Study on the Fluidization and Enhancement Effects of Cineole Toward Stratum Corneum Intercellular Lamellar Lipids: A Liquid Crystalline Model Approach.

Karami L, Moghimi H Iran J Pharm Res. 2023; 22(1):e134731.

PMID: 38116568 PMC: 10728853. DOI: 10.5812/ijpr-134731.

Brain targeting of zolmitriptan via transdermal terpesomes: statistical optimization and in vivo biodistribution study by Tc radiolabeling technique.

Tawfik M, Eltaweel M, Fatouh A, Shamsel-Din H, Ibrahim A Drug Deliv Transl Res. 2023; 13(12):3059-3076.

PMID: 37273147 PMC: 10624728. DOI: 10.1007/s13346-023-01373-0.

Palmitoyl Carnitine-Anchored Nanoliposomes for Neovasculature-Specific Delivery of Gemcitabine Elaidate to Treat Pancreatic Cancer.

Patel A, Saraswat A, Patel H, Chen Z, Patel K Cancers (Basel). 2023; 15(1).

PMID: 36612178 PMC: 9818435. DOI: 10.3390/cancers15010182.

Enhancing the Bioavailability and Efficacy of Vismodegib for the Control of Skin Cancer: In Vitro and In Vivo Studies.

Salem H, Gamal A, Saeed H, Kamal M, Tulbah A Pharmaceuticals (Basel). 2022; 15(2).

PMID: 35215238 PMC: 8874937. DOI: 10.3390/ph15020126.

A Comprehensive Review on Preparation, Evaluation and Applications of Deformable Liposomes.

Nayak D, Tippavajhala V Iran J Pharm Res. 2021; 20(1):186-205.

PMID: 34400952 PMC: 8170744. DOI: 10.22037/ijpr.2020.112878.13997.

References

Pupo E, Padron A, Santana E, Sotolongo J, Quintana D, Duenas S . Preparation of plasmid DNA-containing liposomes using a high-pressure homogenization--extrusion technique. J Control Release. 2005; 104(2):379-96. DOI: 10.1016/j.jconrel.2005.02.001. View

Lahn M, Su C, Li S, Chedid M, Hanna K, Graff J . Expression levels of protein kinase C-alpha in non-small-cell lung cancer. Clin Lung Cancer. 2004; 6(3):184-9. DOI: 10.3816/clc.2004.n.032. View

Sinico C, De Logu A, Lai F, Valenti D, Manconi M, Loy G . Liposomal incorporation of Artemisia arborescens L. essential oil and in vitro antiviral activity. Eur J Pharm Biopharm. 2004; 59(1):161-8. DOI: 10.1016/j.ejpb.2004.06.005. View

Kamimura K, Suda T, Zhang G, Liu D . Advances in Gene Delivery Systems. Pharmaceut Med. 2011; 25(5):293-306. PMC: 3245684. DOI: 10.2165/11594020-000000000-00000. View

Santos P, Watkinson A, Hadgraft J, Lane M . Influence of penetration enhancer on drug permeation from volatile formulations. Int J Pharm. 2012; 439(1-2):260-8. DOI: 10.1016/j.ijpharm.2012.09.031. View

Alinaghi A, Rouini M, Johari Daha F, Moghimi H . Hydrogel-embeded vesicles, as a novel approach for prolonged release and delivery of liposome, in vitro and in vivo. J Liposome Res. 2013; 23(3):235-43. DOI: 10.3109/08982104.2013.799179. View

Movassaghian S, Moghimi H, H Shirazi F, Torchilin V . Dendrosome-dendriplex inside liposomes: as a gene delivery system. J Drug Target. 2011; 19(10):925-32. DOI: 10.3109/1061186X.2011.628396. View

Carter G, Lemoine N . Antisense technology for cancer therapy: does it make sense?. Br J Cancer. 1993; 67(5):869-76. PMC: 1968450. DOI: 10.1038/bjc.1993.164. View

Saffari M, Tamaddon A, Hoseini Shirazi F, Oghabian M, Moghimi H . Improving cellular uptake and in vivo tumor suppression efficacy of liposomal oligonucleotides by urea as a chemical penetration enhancer. J Gene Med. 2013; 15(1):12-9. DOI: 10.1002/jgm.2688. View

10.

Tan Y, Whitmore M, Li S, Frederik P, Huang L . LPD nanoparticles--novel nonviral vector for efficient gene delivery. Methods Mol Med. 2002; 69:73-81. DOI: 10.1385/1-59259-141-8:073. View

11.

Di Maio M, Morabito A, Piccirillo M, Daniele G, Giordano P, Costanzo R . New drugs in advanced non-small-cell lung cancer: searching for the correct clinical development. Expert Opin Investig Drugs. 2010; 19(12):1503-14. DOI: 10.1517/13543784.2010.532122. View

12.

Stuart D, Allen T . A new liposomal formulation for antisense oligodeoxynucleotides with small size, high incorporation efficiency and good stability. Biochim Biophys Acta. 2000; 1463(2):219-29. DOI: 10.1016/s0005-2736(99)00209-6. View

13.

Davies A, Gandara D, Lara Jr P, Mack P, Lau D, Gumerlock P . Antisense oligonucleotides in the treatment of non-small-cell lung cancer. Clin Lung Cancer. 2004; 4 Suppl 2:S68-73. DOI: 10.3816/clc.2003.s.007. View

14.

Song H, Tang Z, Yuan S, Zhu B, Liu X . Antisense candidates against protein kinase C-alpha designed based on phylogenesis and simulant structure of mRNA. Acta Pharmacol Sin. 2003; 24(3):269-76. View

15.

Dominska M, Dykxhoorn D . Breaking down the barriers: siRNA delivery and endosome escape. J Cell Sci. 2010; 123(Pt 8):1183-9. DOI: 10.1242/jcs.066399. View

16.

Cogoi S, Suraci C, Del Terra E, Diviacco S, van der Marel G, van Boom J . Downregulation of c-Ki-ras promoter activity by triplex-forming oligonucleotides endogenously generated in human 293 cells. Antisense Nucleic Acid Drug Dev. 2000; 10(4):283-95. DOI: 10.1089/108729000421466. View

17.

Moghimi H, Williams A, Barry B . Enhancement by terpenes of 5-fluorouracil permeation through the stratum corneum: model solvent approach. J Pharm Pharmacol. 1998; 50(9):955-64. DOI: 10.1111/j.2042-7158.1998.tb06909.x. View

18.

Tamaddon A, H Shirazi F, Moghimi H . Modeling cytoplasmic release of encapsulated oligonucleotides from cationic liposomes. Int J Pharm. 2007; 336(1):174-82. DOI: 10.1016/j.ijpharm.2006.11.048. View

19.

Kanikkannan N, Kandimalla K, Lamba S, Singh M . Structure-activity relationship of chemical penetration enhancers in transdermal drug delivery. Curr Med Chem. 2000; 7(6):593-608. DOI: 10.2174/0929867003374840. View

20.

Genc R, Ortiz M, OSullivan C . Curvature-tuned preparation of nanoliposomes. Langmuir. 2009; 25(21):12604-13. DOI: 10.1021/la901789h. View